Clinical efficacy and impact on immune function of regorafenib combined with Jianpi Xiaoai Formula in treating colorectal cancer
Objective To study the clinical efficacy and impact on immune function of regorafenib combined with Jianpi Xiaoai Formula(JPXAF)in treating colorectal cancer.Methods A total of 70 patients with colorectal cancer admitted to Oncology Department of Nanjing Hospital of Nanjing University of Chinese Medicine(The Second Hospital of Nanjing)from February 2022 to December 2023 were divided into two groups according to the random number table method.The observation group(n=35)was treated with regorafenib combined with JPXAF,while the control group(n=35)were administered with only regorafenib.Both groups were treated for 28 days.The total effective rate was evaluated.Before and after treatment,T lymphocyte(CD3+),helper T cells(CD4+),CD4+/cytotoxic T cells(CD8+),carbohydrate antigens(CA125,CA19-9,CA242),carcinoembryonic antigen(CEA),interleukin-6(IL-6),interleukin-10(IL-10),and tumor necrosis factor-α(TNF-α)were measured.The adverse reactions(such as nausea and vomiting,skin reaction of hands and feet,diarrhea,abnormal function of liver and kidney)were recorded.Results The total effective rate of the observation group was 57.14%,which was higher than the 42.86%in the control group(P<0.05).After treatment,the levels of serum CD3+,CD4+,CD4+/CD8+in both groups were significantly higher than those before treatment(P<0.05),and the levels of CD3+,CD4+,and CD4+/CD8+in the observation group were all higher than those in the control group(P<0.05).After treatment,the levels of CA125,CA19-9,CA242,and CEA in both groups were lower than those before treatment(P<0.05),and the levels of CA125,CA19-9,CA242,and CEA in the observation group were all lower than those in the control group(P<0.05).Post-treatment,the levels of serum IL-6,IL-10,and TNF-α were lower in both groups than before treatment(P<0.05),and the levels of IL-6,IL-10,and TNF-α in the observation group were all lower than those in the control group(P<0.05).During the treatment,there was no statistically significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).Conclusion Regorafenib combined with JPXAF has a good therapeutic effect on colorectal cancer,which can reduce inflammatory response,regulate immune function,and lower tumor marker levels,with few adverse reactions.Therefore,it is worthy of clinical promotion.
国家科技期刊平台
NSTL
万方数据
